Gout attacks halved in atherosclerosis patients treated with canakinumab

The anti-inflammatory biological therapy canakinumab (Ilaris) has been found to more than halve the rate of gout in atherosclerosis patients. In a secondary analysis of data from the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study), which examined the effectiveness of the canakinumab for the prevention of cardiovascular events, the effect on gout was seen regardless of ...

Already a member?

Login to keep reading.

© 2021 the limbic